Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11180MR)

This product GTTS-WQ11180MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11180MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2354MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ9376MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ1921MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ12908MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ3933MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ7897MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ7828MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ9068MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW